Medicinal chemistry of target family-directed masterkeys.

by: G Müller

Drug Discov Today, Vol. 8, No. 15. (1 August 2003), pp. 681-691.

View FullText article

Pubmed, Hubmed

Reviews [Write a review of this article]

There are no reviews of this article

Find related articles from these CiteULike users

Yanno

Find related articles with these CiteULike tags

chemical, design, library, privileged, structure

Abstract

The majority of pharmaceutically relevant drug targets cluster into densely populated target families, thus offering a novel approach that complements the currently favoured screening paradigm in medicinal chemistry. This approach uses a privileged structure concept whereby molecular masterkeys are developed that account for a target family wide structural or functional commonality. Numerous lead compounds, based on multipurpose privileged structures, can be generated that address a variety of targets from a gene family of interest, irrespective of therapeutic area. Several different interpretations of the privileged structure concept will be highlighted, with a strong emphasis on the most stringent application: the optimization of a molecular masterkey for a distinct target family of interest.

@article{citeulike:407940, abstract = {The majority of pharmaceutically relevant drug targets cluster into densely populated target families, thus offering a novel approach that complements the currently favoured screening paradigm in medicinal chemistry. This approach uses a privileged structure concept whereby molecular masterkeys are developed that account for a target family wide structural or functional commonality. Numerous lead compounds, based on multipurpose privileged structures, can be generated that address a variety of targets from a gene family of interest, irrespective of therapeutic area. Several different interpretations of the privileged structure concept will be highlighted, with a strong emphasis on the most stringent application: the optimization of a molecular masterkey for a distinct target family of interest.}, address = {Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, 81377 M\"{u}nich, Germany. gerhard.mueller@axxima.com}, author = {M\"{u}ller, G. }, citeulike-article-id = {407940}, issn = {1359-6446}, journal = {Drug Discov Today}, keywords = {chemical, design, library, privileged, structure}, month = {August}, number = {15}, pages = {681--691}, posted-at = {2005-11-25 09:12:45}, priority = {0}, title = {Medicinal chemistry of target family-directed masterkeys.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/12927511}, volume = {8}, year = {2003} }

RIS record

TY - JOUR ID - citeulike:407940 L3 - citeulike-article-id:407940 N2 - The majority of pharmaceutically relevant drug targets cluster into densely populated target families, thus offering a novel approach that complements the currently favoured screening paradigm in medicinal chemistry. This approach uses a privileged structure concept whereby molecular masterkeys are developed that account for a target family wide structural or functional commonality. Numerous lead compounds, based on multipurpose privileged structures, can be generated that address a variety of targets from a gene family of interest, irrespective of therapeutic area. Several different interpretations of the privileged structure concept will be highlighted, with a strong emphasis on the most stringent application: the optimization of a molecular masterkey for a distinct target family of interest. IS - 15 JF - Drug Discov Today SN - 1359-6446 AD - Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, 81377 Münich, Germany. gerhard.mueller@axxima.com EP - 691 TI - Medicinal chemistry of target family-directed masterkeys. VL - 8 SP - 681 KW - chemical KW - design KW - library KW - privileged KW - structure AU - Müller, G PY - 2003/08/01/ UR - http://view.ncbi.nlm.nih.gov/pubmed/12927511 ER -

RIS BibTeX